Through CCK-8, wound healing and transwell assays, it was evidenced that miR-218-1-3p inhibition could countervail the suppressive influences of TCS treatment on cell proliferative, migratory and invasive abilities, but SLC35C1 deficiency could completely counteract the effects of miR-218-1-3p inhibition (Fig. 5B-C & Supplementary Fig. 1 K, P < 0.01). The gene discussed is SLC35C1; the disease is Treacher-Collins syndrome.